DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 7,678,808 B2 Barlow Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 7,678,808 B2 Barlow Et Al USOO7678808B2 (12) United States Patent (10) Patent No.: US 7,678,808 B2 Barlow et al. (45) Date of Patent: Mar. 16, 2010 (54) 5 HT RECEPTOR MEDIATED 3,960,927 A 6, 1976 Metcalfetal. NEUROGENESIS 4,007,196 A 2f1977 Christensen et al. 4,024, 175 A 5/1977 Satzinger et al. (75) Inventors: Carrolee Barlow, Del Mar, CA (US); 4,036,840 A 7, 1977 O'Brien et al. Todd Carter, San Diego, CA (US); 4,051.236 A 9, 1977 Harris et al. 4,062,848 A 12/1977 Van der Burg Andrew Morse, San Diego, CA (US); 4,085.225Ww - A 4, 1978 W.elle et al. Kai Treuner, San Diego, CA (US); Kym 4,093,617 A 6/1978 Robins et al. I. Lorrain, San Diego, CA (US) 4,094.992 A 6/1978 Kaplanet al. 4,096,257 A 6, 1978 Menschik et al. (73) Assignee: BrainCells, Inc., San Diego, CA (US) 4,107,307 A 8, 1978 Paul et al. 4,107,309 A 8, 1978 Paul et al. (*) Notice: Subject to any disclaimer, the term of this 4,123,534. A 10/1978 Credner et al. patent is extended or adjusted under 35 4,136,193 A 1/1979 Bogeso et al. U.S.C. 154(b) by 27 days. 4,146,718 A 3, 1979 Jenks et al. 4,172,074 A 10, 1979 Eriksoo et al. (21) Appl. No.: 11/746,008 4,188,391 A 2/1980 Campbell et al. 9 4,194,009 A 3/1980 Molloy et al. 1-1. 4,220,646 A 9, 1980 Cotrel et al. (22) Filed: May 8, 2007 4,229,449 A 10/1980 Melloni et al. O O RE30,511 E 2f1981 Paul et al. (65) Prior Publication Data 4.278,676 A 7/1981 Krogsgaard-Larsen US 2007/O270449 A1 Nov. 22, 2007 4,280,957 A 7/1981 Walser et al. 4,289,772 A 9/1981 Campbell et al. Related U.S. Application Data (60) Provisional application No. 60/746,878, filed on May (Continued) 9, 2006, provisional application No. 60/805,436, filed FOREIGN PATENT DOCUMENTS 3. A 2. pal application No. 60/882, EP 00505:51 4f1982 , Illed On Dec. ZRS, EP OO50563 4f1982 EP O356.128 2, 1990 (51) Int. Cl. EP O362001 4f1990 A6 IK 3/44 (2006.01) EP O461986 12/1991 A 6LX 3L/395 (2006.01) EP O463969 1, 1992 A 6LX 3L/2197 (2006.01) EP O503411 9, 1992 A6 IK3I/50 I (2006.01) EP O579496 1, 1994 (52) U.S. Cl. ............. 514/280: 514/210.01: 514/210.21; EP O685479 12/1995 514/222.2: 514/229.8: 514/247; 514/252.16; EP O7O2555 3, 1996 514/359; 514/415 (58) Field of Classification Search ................. 514/280, (Continued) 514/282 OTHER PUBLICATIONS See application file for complete search history. Adachi et al., Selective activation of vitamin D receptor by (56) References Cited lithocholic acid acetate, abile acid derivative, J. Lipid Res.46(1):46 57, 2005. U.S. PATENT DOCUMENTS Adams et al., Omega-Conotoxin CVID inhibits a pharmacologically 1,873,732 A 8, 1932 Adams distinct voltage-sensitive calcium channel associated with transmit 3,109,843. A 11, 1963 Reeder et al. ter release from preganglionic nerve terminals, J. Biol. Chem. 3,116,203 A 12/1963 Kariss et al. 278(6):4057-62, 2003. 3,121,076 A 2f1964 Keller et al. 3,136,815 A 6, 1964 Reeder et al. (Continued) 3.242,190 A 3/1966 Hafliger et al. 3,296,249 A 1, 1967 Bell Primary Examiner Sreeni Padmanabhan 3,371,085 A 2f1968 Reeder et al. Assistant Examiner Sahar Javanmard 3,397.209 A 8/1968 Hafliger (74) Attorney, Agent, or Firm Sughrue Mion PLLC 3,454,554 A 7, 1969 Biel 3,471.548 A 10, 1969 Keberle et al. (57) ABSTRACT 3,534,041 A 10/1970 Van der Burg et al. 3,758,528 A 9, 1973 Malen et al. The instant disclosure describes methods for treating diseases 3,814,812 A 6/1974 Eynard and conditions of the central and peripheral nervous system 3,819,631 A 6/1974 Broughton et al. by stimulating or increasing neurogenesis. The disclosure 3,819,706 A 6, 1974 Mehta et al. 3,821,249 A 6, 1974 Malen et al. includes compositions and methods based on use of a 5HTR 3,862,149 A 1/1975 Cotrel et al. agent, optionally in combination with one or more other 3,885,046 A 5, 1975 Mehta neurogenic agents, to stimulate or activate the formation of 3,912,743 A 10, 1975 Christensen et al. new nerve cells. 3,932,407 A 1/1976 Beverung, Jr. et al. 3,941,785 A 3, 1976 Clarke et al. 3 Claims, 53 Drawing Sheets US 7,678,808 B2 Page 2 U.S. PATENT DOCUMENTS 5,130,154 A 7, 1992 Liu et al. 5,130,430 A 7, 1992 Shaw 4.298,734. A 1 1/1981 Temple, Jr. 5,137,895 A 8/1992 Munson, Jr. et al. 4,301,176 A 11, 1981 Grabowski et al. 5,139,802 A 8, 1992 Liu et al. 4,314,081 A 2/1982 Molloy et al. 5,149,817 A 9, 1992 Matsumura et al. 4,316,839 A 2f1982 Gerecke et al. 5,158,947 A 10/1992 Tatsuoka et al. 4.338,317 A 7/1982 Temple, Jr. et al. 5,162.341 A 11/1992 Cook 4,361,583. A 1 1/1982 Kaplan 5,169,855. A 12/1992 Cain et al. 4,366,156 A 12/1982 Temple, Jr. 5, 182,290 A 1/1993 Albaugh 4,370,328 A 1/1983 Campbell et al. 5,185,446 A 2f1993 Shaw et al. 4,370,338 A 1/1983 Mizoule 5,212,310 A 5/1993 Thurkaufetal. 4,383,999 A 5, 1983 Bondinell et al. 5,216,159 A 6/1993 Thurkaufetal. 4.404,380 A 9/1983 Temple, Jr. 5,232,917 A 8/1993 Bolger et al. RE31,617 E 6/1984 Beverung, Jr. et al. 5,243,049 A 9, 1993 Shaw et al. 4,460,765 A 7, 1984 Naito et al. 5,250,534. A 10/1993 Bell et al. 4,478,836 A 10/1984 Mouzin et al. 5,260.314 A 1 1/1993 Sauerberg et al. 4.489,078 A 12/1984 Temple, Jr. 5,266,698. A 1 1/1993 Shaw et al. 4490,371. A 12/1984 Jones et al. 5,278,170 A 1/1994 Orlek et al. 4.513,006 A 4/1985 Maryanoff et al. 5,286,860 A 2f1994 Blum et al. 4.513,135 A 4/1985 Wong et al. 5,286,864 A 2f1994 Walther et al. 4,521,422 A 6, 1985 DuSZa et al. 5,294,612 A 3, 1994 Bacon et al. 4,536,518 A 8, 1985 Welch, Jr. et al. 5,298,657 A 3, 1994 Durant et al. 4,564,619 A 1, 1986 Tanaka et al. 5,306,819 A 4/1994 Albaugh et al. 4,593,029 A 6, 1986 Venuti et al. 5,312,822 A 5/1994 Albaugh 4,626,538 A 12/1986 Dusza et al. 5,312,840 A 5/1994 Keana et al. 4,642,345 A 2/1987 Temple, Jr. 5,314,901 A 5/1994 Bromidge et al. 4,656.298 A 4, 1987 Dingwall et al. RE34,653 E 7, 1994 Tsukamoto et al. 4,663,320 A 5, 1987 Jones et al. 5,326,868 A 7, 1994 Thurkaufetal. 4,670.434 A 6, 1987 Venuti 5,328,912 A 7/1994 Albaugh 4,699,927 A 10, 1987 Deboeck 5,340,821 A 8, 1994 Abe et al. 4,701.459 A 10, 1987 Meanwell et al. 5,340,827 A 8/1994 Beeley et al. 4,709,094. A 11, 1987 Weber et al. 5,346,901 A 9, 1994 Bell et al. 4,710,508 A 12/1987 Bergmeier et al. 5,356,912 A 10/1994 Nielsen et al. 4,721,784. A 1/1988 Combs 5,356,914 A 10/1994 Bromidge et al. 4,739,056 A 4, 1988 Venuti 5.362,860 A 1 1/1994 Huang et al. 4,761.416 A 8, 1988 Fried et al. 5,367,077 A 11/1994 Blum et al. 4,761,501 A 8, 1988 Husbands et al. 5,369,108 A 1 1/1994 Breslow et al. 4,766,118 A 8, 1988 Combs 5,385,946 A 1/1995 Keana et al. 4,775,674. A 10, 1988 Meanwell et al. 5,395,841 A 3/1995 Foguet et al. 4.786,648 A 1 1/1988 Bergmeier et al. 5,403,931 A 4, 1995 Tsukamoto et al. 4,794,185 A 12/1988 Rossey et al. 5,412,096 A 5/1995 Tsukamoto et al. 4,831,031 A 5/1989 Lowe, III et al. 5,424,301 A 6/1995 Huang et al. 4,855,290 A 8, 1989 Fisher et al. 5,426,186 A 6/1995 Shaw et al. 4,861,891 A 8, 1989 Saccomano et al. 5,451,585 A 9/1995 Albaugh 4,866,077 A 9/1989 Bogeso et al. 5,451,587 A 9, 1995 Walther et al. 4,900,836 A 2f1990 Tomcufcik et al. 5,463,054 A 10, 1995 Thurkaufetal. 4,906.628 A 3, 1990 Coates 5,473,073.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • The Impact of the Nonpeptide Corticotropin-Releasing Hormone Antagonist Antalarmin on Behavioral and Endocrine Responses to Stress*
    0013-7227/99/$03.00/0 Vol. 140, No. 1 Endocrinology Printed in U.S.A. Copyright © 1999 by The Endocrine Society The Impact of the Nonpeptide Corticotropin-Releasing Hormone Antagonist Antalarmin on Behavioral and Endocrine Responses to Stress* TERRENCE DEAK, KIEN T. NGUYEN, ANDREA L. EHRLICH, LINDA R. WATKINS, ROBERT L. SPENCER, STEVEN F. MAIER, JULIO LICINIO, MA-LI WONG, GEORGE P. CHROUSOS, ELIZABETH WEBSTER, AND PHILIP W. GOLD Department of Psychology (T.D., K.T.N., A.L.E., L.R.W., R.L.S., S.F.M.), University of Colorado, Boulder, Colorado 80309-0345; Clinical Neuroendocrinology Branch (J.L., M.-L.W., P.W.G.), National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892-1284; and Developmental Neuroendocrinology Branch (G.P.C., E.W.), National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-1284 ABSTRACT Furthermore, because rats previously exposed to inescapable shock The nonpeptide CRH antagonist antalarmin has been shown to (IS; 100 shocks, 1.6 mA, 5 sec each), demonstrate enhanced fear block both behavioral and endocrine responses to CRH. However, it’s conditioning, we investigated whether this effect would be blocked by potential activity in blunting behavioral and endocrine sequelae of antalarmin. Antalarmin (20 mg/kgz2 ml ip) impaired both the induc- stressor exposure has not been assessed. Because antagonism of cen- tion and expression of conditioned fear. In addition, antalarmin tral CRH by a-helical CRH attenuates conditioned fear responses, we blocked the enhancement of fear conditioning produced by prior ex- sought to test antalarmin in this regard.
    [Show full text]
  • Adverse Effects of Stress on Drug Addiction
    Making a bad thing worse: adverse effects of stress on drug addiction Jessica N. Cleck, Julie A. Blendy J Clin Invest. 2008;118(2):454-461. https://doi.org/10.1172/JCI33946. Review Series Sustained exposure to various psychological stressors can exacerbate neuropsychiatric disorders, including drug addiction. Addiction is a chronic brain disease in which individuals cannot control their need for drugs, despite negative health and social consequences. The brains of addicted individuals are altered and respond very differently to stress than those of individuals who are not addicted. In this Review, we highlight some of the common effects of stress and drugs of abuse throughout the addiction cycle. We also discuss both animal and human studies that suggest treating the stress- related aspects of drug addiction is likely to be an important contributing factor to a long-lasting recovery from this disorder. Find the latest version: https://jci.me/33946/pdf Review series Making a bad thing worse: adverse effects of stress on drug addiction Jessica N. Cleck and Julie A. Blendy Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. Sustained exposure to various psychological stressors can exacerbate neuropsychiatric disorders, including drug addiction. Addiction is a chronic brain disease in which individuals cannot control their need for drugs, despite negative health and social consequences. The brains of addicted individuals are altered and respond very differently to stress than those of individuals who are not addicted. In this Review, we highlight some of the common effects of stress and drugs of abuse throughout the addiction cycle.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Epidemiology of Depressive Disorders 21 Aetiology 22 Treatment of Depressive Disorders 40 Prognosis 51
    The assessment of serotonin function in major depression MD Thesis William Richard Whale 2005 1 UMI Number: U201052 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. Dissertation Publishing UMI U201052 Published by ProQuest LLC 2014. Copyright in the Dissertation held by the Author. Microform Edition © ProQuest LLC. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Abstract Major depression is a common psychiatric disorder with considerable associated morbidity and mortality. Investigations to understand the causes of depression and how it can be more effectively treated are high priority. The serotonergic system has been implicated in the aetiology and treatment of depression by a wealth of preclinical and clinical evidence. This includes findings that drugs increasing serotonin neurotransmission have antidepressant action and inhibition of serotonin synthesis (via tryptophan depletion) can induce relapse of symptoms in depressed patients. Neuroendocrine challenges are an established method of indirectly examining brain serotonergic function, utilising changes in the secretion of pituitary hormones influenced by tonic serotonergic activity at the level of the hypothalamus. This thesis describes the development of two such neuroendocrine challenge tests, using the selective serotonergic probes, zolmitriptan and citalopram. Orally administered zolmitriptan, licensed for the treatment of migraine, clearly elevated plasma growth hormone in healthy subjects.
    [Show full text]
  • A Randomized Double-Blind, Double-Dummy
    pISSN 1598-2998, eISSN 2005-9256 Cancer Res Treat. 2014;46(1):19-26 http://dx.doi.org/10.4143/crt.2014.46.1.19 Original Article Open Access A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy Hee Yeon Lee, MD 1 Purpose Hoon-Kyo Kim, MD 1 This study was conducted to evaluate the efficacy and safety of azasetron compared Kyung Hee Lee, MD 2 to ondansetron in the prevention of delayed chemotherapy-induced nausea and Bong-Seog Kim, MD 3 vomiting. MD 4 Hong Suk Song, Materials and Methods MD 5 Sung Hyun Yang, This study was a multi-center, prospective, randomized, double-dummy, double-blind MD 6 Joon Hee Kim, and parallel-group trial involving 12 institutions in Korea between May 2005 and MD 7 Yeul Hong Kim, December 2005. A total of 265 patients with moderately and highly emetogenic MD 8 Jong Gwang Kim, chemotherapy were included and randomly assigned to either the azasetron or MD 9 Sang-We Kim, ondansetron group. All patients received azasetron (10 mg intravenously) and MD 10 Dong-Wan Kim, dexamethasone (20 mg intravenously) on day 1 and dexamethasone (4 mg orally every MD 11 Si-Young Kim, 12 hours) on days 2-4. The azasetron group received azasetron (10 mg orally) with MD 12 Hee Sook Park, placebo of ondansetron (orally every 12 hours), and the ondansetron group received Department of Internal Medicine, ondansetron (8 mg orally every 12 hours) with placebo of azasetron (orally) on days 1St.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • A Synthetic Overview of New Molecules with 5-HT1A Binding Affinities
    77 A Synthetic Overview of New Molecules with 5-HT1A Binding Affinities Hernán Pessoa-Mahana* 1 ; Ramiro Araya-Maturana1 , Claudio Saitz, B.1 and C. David Pessoa-Mahana2 1Departamento de Química Orgánica y Fisicoquímica. Facultad de Ciencias Químicas y Farmacéuticas. Universidad de Chile. Olivos 1007.Casilla 233. Santiago 1. Chile 2Departamento de Farmacia. Facultad de Química. Pontificia Universidad Católica de Chile. Vicuña Mackenna 4860-Casilla 306, Correo 22 Santiago-Chile Abstract: The present review discusses the synthetic strategies of new ligands exhibiting mainly 5-HT1A binding affinities. Specifically we focused our attention in the synthesis of compounds structurally related to arylpiperazine, 2-aminotetralin, and benzopyran derivatives. Keywords: serotonin, 5-HT1A ligands, arylpiperazines, aminotetralins, benzopyrans. INTRODUCTION During the last 15 years, seven distinct families of 5-HT receptors have been identified (5-HT1–5-HT7), and at least Depression is one of the most common illnesses, 15 subpopulations have been described for several of these affecting up to one-third of all people at the same time. [4,5]. The 5-HT1A receptors represent a major target for Depressive disorders encompass a variety of conditions neurobiological research and drug developments. A study on including two major forms of unipolar depression (i.e. major distribution of 5-HT1A receptors in the brains of various depression and dysthymia), adjustment disorders, animal species indicates that the highest densities are located subsyndromal depression (minor depression), seasonal in the hippocampus, septum, amygdale, and cortical limbic affective disorder (SAD), premenstrual dysphoric disorder areas. The 5-HT1A receptors located in the raphe nuclei are (PMDD), postpartum depression, atypical depression and known as somatodendritic autoreceptors.
    [Show full text]
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Group II/III Metabotropic Glutamate Receptors Exert Endogenous Activity-Dependent Modulation of TRPV1 Receptors on Peripheral Nociceptors
    The Journal of Neuroscience, September 7, 2011 • 31(36):12727–12737 • 12727 Behavioral/Systems/Cognitive Group II/III Metabotropic Glutamate Receptors Exert Endogenous Activity-Dependent Modulation of TRPV1 Receptors on Peripheral Nociceptors Susan M. Carlton, Shengtai Zhou, Rosann Govea, and Junhui Du Department of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, Texas 77555-1069 There is pharmacological evidence that group II and III metabotropic glutamate receptors (mGluRs) function as activity-dependent autoreceptors, inhibiting transmission in supraspinal sites. These receptors are expressed by peripheral nociceptors. We investigated whether mGluRs function as activity-dependent autoreceptors inhibiting pain transmission to the rat CNS, particularly transient recep- tor potential vanilloid 1 (TRPV1)-induced activity. Blocking peripheral mGluR activity by intraplantar injection of antagonists LY341495 [(2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid] (LY) (20, 100 ␮M, group II/III), APICA [(RS)-1- amino-5-phosphonoindan-1-carboxylic acid] (100 ␮M, group II), or UBP1112 (␣-methyl-3-methyl-4-phosphonophenylglycine) (30 ␮M, groupIII)increasedcapsaicin(CAP)-inducednociceptivebehaviorsandnociceptoractivity.Incontrast,groupIIagonistAPDC[(2R,4R)- 4-aminopyrrolidine-2,4-dicarboxylate] (0.1 ␮M) or group III agonist L-(ϩ)-2-amino-4-phosphonobutyric acid (L-AP-4) (10 ␮M) blocked the LY-induced increase. Ca 2ϩ imaging in dorsal root ganglion (DRG) cells confirmed LY enhanced CAP-induced Ca 2ϩ mobilization, which was blocked by APDC and L-AP-4. We hypothesized that excess glutamate (GLU) released by high intensity and/or prolonged stimulation endogenously activated group II/III, dampening nociceptor activation. In support of this, intraplantar GLU ϩ LY produced heat hyperalgesia, and exogenous GLU ϩ LY applied to nociceptors produced enhanced nociceptor activity and thermal sensitization.
    [Show full text]